Compliance Trainings, Canada
2015-01-21
This webinar will discuss about two “Strategic Priorities” that the FDA has published to emphasize their future directions vis a vis regulated industry and public safety. Each year companies are to perform a complete review of their quality management system and its ability to meet the current GMP's. The FDA has added a "Strategic Priorities" initiative that can assist companies to proactively address areas of GMP concern -- there are now two such reports – we will discuss both, emphasizing the latest “draft for public comment”, for 2014 - 2018. The reports reflect a major shift in the emphasis of the U.S. FDA cGMP compliance audits, clinical trial expectations, product submissions and company response requirements. In short, all regulatory areas are under evaluation by the FDA, and need to be revisited by a company's QA/RA and its senior management / staff. This change in focus has a major impact on interpretation of individual compliance objectives, cGMP objectives, and measurements of success. Ongoing negative publicity on pharmaceuticals, devices, as well as events in unrelated industries show many senior executives just don't get it, and have put pressure on the Agency to "get tough on compliance / enforcement". This webinar will trigger such a response by an examination / review of FDA's stated concerns for corporate cGMP compliance and public safety. Areas Covered in the Session : Major “Drivers” and New U.S. FDA Initiatives The FDA’s “Strategic Priorities” (1): 2011 – 2014 The FDA’s “Strategic Priorities” (2): 2014 – 2018 Major foreseeable problem areas for 2015 and beyond Device, Pharmaceutical, Biological and Combination Products Issues cGMP Issues - Strengthened Compliance The Global Supply Chain FDA's Life Cycle Requirements Navigating through "Better Science" A company gap analysis vis a vis FDA priorities Correcting problem-prone areas Interactive Q & A session Who Will Benefit: This webinar will provide valuable assistance to all U. S. FDA-regulated companies. It will assist in their reviewing and modifying their regulatory compliance stance in view of the areas the FDA indicates are of growing / future interest / emphasis. Its principles apply to personnel / companies in the Medical Devices, Pharmaceutical, Diagnostic, and Biologics fields. The employees who will benefit include: Research & Development Engineering Staff Software Department Quality Assurance Regulatory Affairs Manufacturing Operations cGMP instructors Consultants Mid-level and Senior Management Personnel involved in verification and/or validation Personnel involved in planning, execution and documentation Price Tags: Live Single Live : For One Participant $ 249 Corporate Live : For Max. 10 Participants $ 899 Recording Single REC : For One Participant - Unlimited Access for 6 Months $ 299 For more information and enquiries contact us at Compliance Trainings 5939 Candlebrook Ct, Mississauga, ON L5V 2V5, Canada Customer Support : #416-915-4458 Email : support@compliancetrainings.com
|